Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
Express News | Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer
Press Release: Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Craig-Hallum Maintains Lifecore Biomedical(LFCR.US) With Buy Rating, Announces Target Price $10
$LFCR Stock Is up 13% Today. Here's What We See in Our Data.
In the Wake of Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Latest US$65m Market Cap Drop, Hedge Funds Owners May Be Forced to Take Severe Actions
Barrington Maintains Lifecore Biomedical(LFCR.US) With Hold Rating
12 Health Care Stocks Moving In Friday's Intraday Session
Lifecore Biomedical Shares Are Trading Lower After the Company Reported a Q3 EPS Miss.
Lifecore Biomedical (LFCR) Gets a Hold From Barrington
Lifecore Biomedical Inc (LFCR) Q3 2025 Earnings Call Highlights: Navigating Challenges With ...
Lifecore Biomedical Targets 12% Revenue CAGR and Expanded CDMO Pipeline by 2027
LIFECORE BIOMEDICAL Earnings Results: $LFCR Reports Quarterly Earnings
Lifecore Biomedical Q3 Swings to Loss, Revenue Lower
Lifecore Biomedical | 10-Q: Q3 2025 Earnings Report
Lifecore Biomedical | 8-K: Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update
Lifecore Biomedical Q3 2025 GAAP EPS $(0.47) Misses $(0.15) Estimate, Sales $35.154M Beat $33.229M Estimate